Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 4/20 | 0.36 |
| ▸ | PDE2A | O00408 | 4/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.35 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.33 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | PNMT | P11086 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL699200 | 0.83 | — | — | |
| SCHEMBL4419662 | 0.79 | MEN1 (0.42) | TSHRMAPK1 | |
| SCHEMBL143472 | 0.79 | IKBKB (0.43) | KIF11TSHRMAPK1ALDH1A1NOTUM | |
| SCHEMBL2869063 | 0.79 | TSHR (0.39) | KIF11TSHRMAPTALDH1A1 | |
| SCHEMBL4580414 | 0.79 | ESR1 (0.41) | TSHRALDH1A1 | |
| SCHEMBL3220922 | 0.78 | — | — | |
| SCHEMBL147631 | 0.78 | KIF11 (0.45) | KIF11ALDH1A1 | |
| SCHEMBL4437593 | 0.77 | NOTUM (0.43) | KIF11PDE2AMAPTNOTUM | |
| SCHEMBL2865616 | 0.76 | ESR1 (0.43) | TSHRALDH1A1 | |
| SCHEMBL3945118 | 0.76 | ESR1 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 368 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208902-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-06-27 | — | — | US | claimed |
| EP-3750894-B1 | UREA-SUBSTITUTED AROMATIC RING-LINKED DIOXAZOLINE COMPOUND, PREPARATION METHOD THEREFOR, AND USES THEREOF | BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) | 2024-04-03 | — | — | EP | claimed |
| US-20240002344-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR HISTONE LYSINE DEMETHYLASE INHIBITION | FIBROGEN, INC. | 2024-01-04 | — | — | US | claimed |
| US-11802111-B2 | Cyclobutyl amide monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-31 | — | — | US | claimed |
| EP-4204400-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR HISTONE LYSINE DEMETHYLASE INHIBITION | Fibrogen, Inc. (US) | 2023-07-05 | — | — | EP | claimed |
| CN-116348450-A | Compounds, compositions and methods for histone lysine demethylase inhibition | 菲布罗根有限公司 | 2023-06-27 | — | — | CN | claimed |
| CN-116323557-A | Cyclobutylamide monoacylglycerol lipase modulators | 詹森药业有限公司 | 2023-06-23 | — | — | CN | claimed |
| CN-110023309-B | Indazole derivatives as glucagon receptor antagonists | 詹森药业有限公司 | 2022-08-09 | — | — | CN | claimed |
| CN-109923109-B | Indazole derivatives as glucagon receptor antagonists | 詹森药业有限公司 | 2022-06-17 | — | — | CN | claimed |
| CN-111757885-B | Urea-substituted aromatic ring-connected dioxane quinoline compound and preparation method and application thereof | 北京赛特明强医药科技有限公司 | 2021-01-29 | — | — | CN | claimed |
| EP-1695974-A1 | 1,8-Naphthyridines as CRF antagonists | GLAXO GROUP LIMITED (GB) | 2006-08-30 | — | — | EP | claimed |
| EP-1425280-B1 | HETERO-BICYCLIC CRF ANTAGONISTS | GLAXO GROUP LTD (GB) | 2006-08-30 | — | — | EP | claimed |
| EP-1383498-B1 | CRF RECEPTOR ANTAGONISTS | GLAXO GROUP LTD (GB) | 2006-03-15 | — | — | EP | claimed |
| EP-1425281-B1 | Tricyclic CRF receptor antagonists | SB PHARMCO PUERTO RICO INC CSC (PR) | 2006-02-01 | — | — | EP | claimed |
| EP-1611133-A1 | CONDENSED N-HETEROCYCLIC COMPOUNDS AND THEIR USE AS CRF RECEPTOR ANTAGONISTS | SB PHARMCO PUERTO RICO INC. CSC, The United States Corporation Company (PR) | 2006-01-04 | — | — | EP | claimed |
| US-20050090546-A1 | Aspartic protease inhibitors | GOVERNMENT OF THE USA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2005-04-28 | — | — | US | claimed |
| WO-2004094420-A1 | CONDENSED N-HETEROCYCLIC COMPOUNDS AND THEIR USE AS CRF RECEPTOR ANTAGONISTS | SB PHARMCO PUERTO RICO INC (US) | 2004-11-04 | — | — | WO | claimed |
| US-6613764-B1 | Compounds such as N,N-dibenzylphenylalanine benzyl ester, used as enzyme inhibitors; prophylaxis of lymphadenopathy associated virus, cancer and malaria | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2003-09-02 | — | — | US | claimed |
| EP-1140846-A1 | ASPARTIC PROTEASE INHIBITORS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2001-10-10 | — | — | EP | claimed |
| WO-2000040558-A1 | ASPARTIC PROTEASE INHIBITORS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2000-07-13 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208902-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, PNLIP | KIF11 3684/4885PDE2A 570/4885TSHR 1023/4885 |
| US-20240002344-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR HISTONE LYSINE DEMETHYLASE INHIBITION | KDM5C, KDM5B, KDM5A | KIF11 3065/4885PDE2A 1218/4885TSHR 4662/4885 |
| US-11802111-B2 | Cyclobutyl amide monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | KIF11 3646/4885PDE2A 562/4885TSHR 1036/4885 |
| US-20050090546-A1 | Aspartic protease inhibitors | DPP7, SENP7, DNPEP | KIF11 4067/4885PDE2A 3709/4885TSHR 1027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.